Lung cancer remains the most frequent cause of cancer death globally. Non-small cell lung cancer (NSCLC) accounts for 80--85% of lung cancers[@b1]. Surgery is the most promising treatment modality for potential cure. However, even patients with stage I NSCLC suffer a 30% risk of relapse after resection[@b2]. In addition, a great majority of patients, approximately 80%, are diagnosed in advanced stages[@b3]. In spite of the improvements in diagnostic and therapeutic techniques on lung cancer over the past few decades, the prognosis is still poor, with an estimated survival of only 15% at 5 years[@b4]. In recent years, many independent clinical and biological prognostic factors for lung cancer have been reported, such as stage, performance status (PS), age, K-ras oncogene mutations, Ki-67 expression, p16 promoter hypermethylation and excision repair cross-complementing 1 (ERCC1) polymorphism[@b5][@b6][@b7][@b8]. Correct identification of molecular prognostic factors may contribute to a better understanding of cancer development, clinical outcome, and eventually facilitate the rational selection of therapeutic strategies.

CYFRA 21--1 is a fragment of cytokeratin (CK) 19 and CKs are the principal structural elements of the cytoskeleton of epithelial cells, including bronchial epithelial cells. CK19 is expressed in the unstratified or pseudostratified epithelium lining the bronchial tree, and been reported to be overexpressed in many lung cancer tissue specimens. The CYFRA 21--1 expression patterns in tissues are well-maintained even during the process of transformation of the tissue from normal to tumor tissue[@b9][@b10]. Many studies demonstrated high expression and diagnostic value of CYFRA 21--1 in NSCLC[@b11]. Also, some researches reported that CYFRA 21--1 expression was associated with metastatic lymph nodes, TNM stage, tumor size, and differentiation[@b12]. CYFRA 21-1 has been identified to be a sensitive biomarker in NSCLC. It was reported that the sensitivity of CYFRA 21-1 in diagnosis of squamous cell carcinoma was 62%[@b13]. Following the fist identification of high serum CYFRA 21-1 level as a valuable prognostic marker in lung cancer patients in 1993[@b14], numerous studies have been performed to validate the result. A meta-analysis of the prognostic role of serum CYFRA 21-1 for NSCLC was reported in 2004[@b15]. They analyzed the data from 1993 to 2001, and demonstrated that a high serum CYFRA 21-1 level was correlated with poor prognosis for NSCLC patients whatever the planned treatment. However, the result of the patients having undergone surgery only showed a trend of statistical significance. Furthermore, this meta-analysis had the following limitations: relatively short follow-ups, including a small number of accrued patients, and not providing detailed treatments for patients who did not undergo surgery.

Subsequently, many studies investigating the role of serum CYFRA 21-1 with more updated therapeutic strategies for NSCLC and larger numbers of accrued patients have been performed[@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46]. However, these studies yielded conflicting results. Therefore, we conducted an updated meta-analysis using data from these studies to reappraise the effect of serum CYFRA 21-1 on the prognosis in patients with NSCLC.

Results
=======

Characteristics of eligible studies
-----------------------------------

After deleting the duplications, a total of 570 potentially relevant publications were collected after initial search. Among these, 313 articles related to the prognosis of lung cancer were reserved. Then 89 studies primarily researching the CYFRA 21-1 level were selected in full text for further screening after reviewing the abstracts. 49 studies were excluded for only investigating the clinical characteristics rather than specific OS, involving small cell lung cancer (SCLC), or other out of the scope according to the inclusion and exclusion criteria, consequently leaving 40 available for further review. After carefully reading, 31 studies, with a total number of 6394 patients were identified in this meta-analysis ([Figure 1](#f1){ref-type="fig"}). Some studies reported two endpoints, and they were analyzed separately. The main characteristics of the evaluable studies were listed in [Table 1](#t1){ref-type="table"}.

In the present meta-analysis, statistical calculations for OS were performed in 31 studies. Sample size of studies ranged from 48 to 1202. 17 studies were performed in Asian, 13 studies were in Caucasian, and one study was in mixed populations. 6 studied NSCLC patients at stage I--IIIA, 9 studied patients at stage IIIB--I, and 15 studied the wide range of stage I--IV. 12 were conducted prospectively, 17 were performed retrospectively, and 2 were not available. The numbers of studies reported all of the patients with surgery and without surgery were 9 and 9, respectively. 7 studies including 1061 patients were involved in PFS calculation. The detailed information of them was described in [Table 1](#t1){ref-type="table"}.

Serum CYFRA 21-1 was dichotomized into high and low levels, and different cut-off value was selected in each study. Most of the studies utilized the manufacturer\'s instructions, some applied the median or mean levels as cut-off values, and the remaining studied defined the value by themselves or a ROC curve.

Main results
------------

The main results of the meta-analysis were listed in [Table 2](#t2){ref-type="table"}. Among the 31 trials eligible for assessing the relationship between CYFRA 21-1 and OS, the pooled HR was 1.60 (95%CI = 1.36--1.89; *P* \< 0.001) ([Figure 2](#f2){ref-type="fig"}), indicating that high serum CYFRA 21-1 level predicted poor OS for NSCLC. In the subgroup analysis by TNM stage, for patients with NSCLC at stage I--IIIA (resected tumor), the pooled HRs were 2.18 (95%CI = 1.70, 2.80; *P* = 0.347) and for stage IIIB--IV (unresectable disease), the pooled HRs were 1.47 (95%CI = 1.02, 2.11; *P* \< 0.001) while for mixed stage I--IV, HRs were 1.52 (95%CI = 1.24, 1.88; *P* \< 0.001), indicating a significant association between high serum lever of CYFRA 21-1 and poor clinical outcome ([Figure 2](#f2){ref-type="fig"}). Then to evaluate the prognostic roles in surgical intervention, we divided the studies into surgery group and non-surgery group and found a pool HR of 1.94 (95%CI = 1.42, 2.67; *P* \< 0.001) for surgery group and 1.24 (95%CI = 0.79--1.95; *P* \< 0.001) for non-surgery group ([Figure 3](#f3){ref-type="fig"}).

When stratified by ethnicity, a pooled HR was 1.62 (95%CI = 1.25--2.09; *P* \< 0.001) for Asians and 1.60 (95%CI = 1.31--1.95; *P* \< 0.001) for Caucasians ([Figure 4](#f4){ref-type="fig"}), favoring the association between high serum CYFRA 21-1 level and poor prognosis. In the subgroup analysis according to study design, a significant link was also found in prospective studies 1.58 (95% CI = 1.27--1.96, *P* *=* 0.001) and retrospective studies 1.75 (95% CI = 1.38--2.22, *P* \< 0.001), respectively ([Supplementary Fig. S1](#s1){ref-type="supplementary-material"}).

When sub-grouped by the chemotherapeutic regimens, the pooled HRs were 1.83 (95%CI = 1.31--2.58; *P* = 0.011) for studies using EGFR-TKIs, and 1.53 (95%CI = 1.53--1.99; *P* = 0.001) for studies applying platinum-based chemotherapy ([Figure 5](#f5){ref-type="fig"}), again, indicating a relationship between high serum CYFRA 21-1 level and poor outcome for NSCLC.

Meta-analysis of PFS was conducted in 7 studies. The pooled HR was 1.41 (95%CI = 1.19--1.69; *P* \< 0.001). Statistically significant effect on PFS was found for serum CYFRA 21-1.

We also performed sensitivity analyses by repeatedly deleting the single studies each time from pooled analysis to examine the stability and reliability of meta-analysis results. In our analysis, the omission of individual studies did not materially alter the results because the recalculated ORs and 95%CIs were not quantitatively changed, suggesting that the results were robust and convincing ([Supplementary Fig. S2, S3](#s1){ref-type="supplementary-material"}).

Publication bias
----------------

Publication bias was assessed by Begg\'s funnel plot and Egger\'s test. Publication bias was detected (*P* = 0.144 for Begg\'s test but *P* *=* 0.03 for Egger\'s test) for pooled OS. Thus, a trim and fill method was utilized and pooled ORs were recalculated with hypothetically non-published studies to evaluate the asymmetry in the funnel plot[@b47] ([Figure 6](#f6){ref-type="fig"}). The recalculated ORs for OS did not change significantly (HR = 1.27; 95% CI = 1.075--1.493; *P* \< 0.001), indicating the stability of the results. However, significant publication bias was not discovered among the studies regarding PFS (*P* = 0.368 for Begg\'s test).

Discussion
==========

To the best of our knowledge, we demonstrated, for the first time, that high serum CYFRA 21-1 level was an indicator of poor prognosis for NSCLC using updated data. Notably, our meta-analysis included three times more patients than the previously reported one[@b15], and the studies employed more updated therapeutic regimen and patients with longer follow-ups. As a result, we were able to show a more plausible result.

In this meta-analysis, we identified 31 eligible studies including 6394 patients and concluded that high serum CYFRA 21-1 level was a poor prognostic indicator for OS and PFS. For different pathological TNM stage, high serum CYFRA 21-1 level was associated with poor clinical outcome of NSCLC patients. Thus, high level of serum CYFRA 21-1 might be a negative prognostic biomarker in NSCLC patients with resected tumor or with unresectable disease. This link was observed in surgery subgroups. Notably, we verified the poor prognostic role of high serum CYFRA 21-1 level in the patients who had undergone surgery (HR = 1.94; 95%CI = 1.42--2.67; *P* \< 0.001), while the previous meta-analysis only indicated a trend towards statistical significance (HR = 1.41, 95% CI = 0.99--2.03, *P* = 0.055). However, for patients who did not undergo surgery, the HR was 1.24 (95%CI = 0.79--1.95; *P* \< 0.001) while the previous meta-analysis showed high serum CYFRA 21-1 level predicted poor survival (HR = 1.78; 95%CI = 1.54--2.07, *P* \< 0.001) in the first year of follow-up[@b15].

We also found that high serum CYFRA 21-1 level was a poor prognostic factor for patients treated with EGFR-TKIs or platinum-based regimen. Platinum-based chemotherapy could improve survival and has become the standard chemotherapy for years[@b48][@b49], however, the efficacy of platinum-based chemotherapy varies among individuals, with a response rate of 26%--60%[@b50]. Various tumor markers have been studied in terms of their prognostic or predictive roles in NSCLC patients treated with platinum-based chemotherapy[@b8][@b51][@b52][@b53][@b54]. However, to date, no serum maker is currently recommended for routine clinical practice in prognosis of NSCLC patients treated with platinum-based chemotherapy. Based on our findings, serum CYFRA 21-1 might be a promising biomarker. EGFR mutations have been reported to be the most important prediction factor for patients treated with EGFR-TKIs[@b55]. Unfortunately, it is not feasible to obtain an adequate EGFR mutational analysis. Therefore, it is important to identify easily acquired clinical parameters that can serve as surrogate markers for EGFR mutants. Our results suggested that serum CYFRA 21-1 might play such a role in the prediction and prognosis of advanced NSCLC treated with EGFR-TKIs. Notably, this was the firstly pooled analysis to verify the prognostic role of serum CYFRA 21-1 in the NSCLC patients treated with platinum-based chemotherapy or EGFR-TKIs. In consideration of the relatively small sample size, large scale prospective studies are needed to further confirm the results.

The sub-group analyses by ethnicity and study design yielded the same results, further indicating the poor prognosis role of high serum CYFRA 21-1 level in NSCLC.

Attention must be paid to the relatively large heterogeneity among trials. Meta-regression was conducted by ethnicity, surgical intervention, chemotherapy, detective method, cutoff, study design, and sample size. However, none of them was found to be the sources of heterogeneity. In fact, many other factors may also be the potential source of heterogeneity, such as gender, age, and life styles of patients and so on. Due to lack of detailed data, we had to give up performing a meta-regression utilizing these variables. Publication bias is significant threat to the reliability of the results of a meta-analysis. Unfortunately, we did find publication bias by Begg\'s funnel plot and Egger\'s test. Then a trim and fill method was adopted to recalculate the adjusted ORs and the results did not change significantly, indicating the stability of the statistic analyses[@b47].

Several limitations have to be noted in relation to this meta-analysis. First, all our analyses were based on abstracted data and not on individual patient data (IPD). It was commonly acknowledged that an IPD-based meta-analysis would reproduce more reliable estimation compared with one based on abstracted data[@b56], while an IPD-based meta-analysis is a time-consuming effort, especially when some studies without high quality[@b57]. Second, several HRs were obtained based on the survival curves, which might have biased our results. Third, cutoff values were different among the studies. Finally, the publication bias and heterogeneity in the meta-analysis may partly lessen its statistical power. However, these problems are almost inevitable in a meta-analysis.

In conclusion, our meta-analysis, based on an updated data, found a significant prognostic value of serum CYFRA 21-1. High serum CYFRA 21-1 level is correlated with poor OS and PFS in NSCLC, which might provide a simple and practical method to predict the outcome of NSCLC patients. Interestingly, serum CYFRA 21-1 is also related to the OS in the NSCLC patients treated with EGFR-TKIs or platinum-based regimen. But the sample size is relatively small, and more investigations are needed to identify its prognostic role in this part of NSCLC patients.

Methods
=======

Search strategy
---------------

To update the data, we intended to exclude the studies accrued in the previous meta-analysis published in 2004[@b15]. Therefore, only those studies published after January 1, 2002, were eligible. We conducted a computerized literature search of Embase, Web of Science, PubMed and China National Knowledge Infrastructure (CNKI) to identify all the studies that studied the association of serum CYFRA 21-1 lever and lung cancer. The combination of the following key words were used as search terms separately and in combination: "CYFRA 21-1", "cytokeratin 19", "non-small cell lung cancer", "NSCLC", "prognosis", "survival", and "outcome". Last search was updated on January 08, 2015. The references of all publications and reviews were manually searched to identify potentially relevant studies.

Inclusion and exclusion criteria
--------------------------------

To be eligible for inclusion in this meta-analysis, studies had to meet the following criteria: (1) trials had to deal with NSCLC; (2) investigating the association between serum CYFRA 21-1 level and prognosis; (3) CYFRA 21-1 was clarified as "high" and "low" value; (4) published as a full paper in English for data extraction; and (5) including enough blood sample. To avoid duplication of data, only the most complete and recent study was included. Titles and abstracts of searching records were screened and full text papers were further evaluated to confirm the eligibility. According to the inclusion criteria, two reviewers (Youtao Xu and Mantang Qiu) extracted eligible studies independently, and disagreement between the two reviewers was settled by discussing with the third reviewer (Lei Xu).

Data extraction
---------------

Two reviewers (Xu and Qiu) determined study eligibility independently in order to avoid selection bias in the data abstraction process. The following information was culled from each study: the first author, publication year, country where the research was performed, ethnicity, number of patients, histology, stage, detective method, cutoff, study design, and survival data. The primary endpoint was OS. The studies utilizing PFS were also analyzed.

Statistical analysis
--------------------

To evaluate the predictive ability of high serum CYFRA 21-1 level on survival of NSCLC, the hazard ratios (HRs) and their 95% confidence intervals (CIs) of OS and PFS were extracted from eligible studies. If these data were not available, the HRs and CI were calculated according to Tierney\' methods[@b58]. The heterogeneity among studies was evaluated using the Cochran Q and *I*^*2*^ test: for the Q test, a *P* \< 0.1 was considered statistically significant[@b59]. For *I*^*2*^ test, a value \>50% was considered a severe heterogeneity[@b60], then the random-effects model (based on DerSimonian-Laird method) was used[@b61]; otherwise, the fixed-effects model (based on Mantel-Haenszel method) was applied. Meta-regression was performed to assess the sources of heterogeneity by ethnicity, surgical intervention, chemotherapy, detective method, cutoff, study design, and sample size (studies with less 200 participants were categorized as "small", and studies with more than 200 participants were categorized as "large"). Between study, variance Tau-squared (τ2) value was used to evaluate the degree of heterogeneity and describe the extent of heterogeneity explained[@b62]. Sensitivity analysis was performed to examine the stability of the pooled results. Publication bias was evaluated by a funnel plot with Egger\'s test and Begg\'s test, and a *P* \< 0.05 was considered significant[@b63]. All statistical analyses were calculated with STATA software (version 12.0; StataCorp, College Station, Texas USA). And all P values were two-side.
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###### Characteristics of studies included in this meta-analysis

  Author       Year   Country   Ethnicity   Surgery   Chemotherapy     TNM      Design    N     Follow-up(month)   Biomarkers   Method   Cutoff   High/low   HR-E   AHR    ALL     AUL
  ----------- ------ --------- ----------- --------- -------------- ---------- -------- ------ ------------------ ------------ -------- -------- ---------- ------ ------ ------ -------
  Lin          2012    China      Asian       Yes         PB/A       IB-IIIA      R      169       53(3--66)           OS       ECLIA     3.30     63/106     HR    1.70   1.19   2.44
  Tanaka       2013    Japan      Asian       NA         TKI/M       IIIB/IV      R      160    32.5(23.3--44.6)     PFS/OS     ECLIA     2.00     83/77      HR    1.10   0.85   1.41
  Park         2013    Korea      Asian       Yes          NA         I--III      R      298    43.3(0.5--95.6)      PFS/OS     ECLIA     1.95    114/184     HR    1.10   1.01   1.20
  Trapé        2012    Spain    Caucasion     No          PB/M       IIIA--IV     P      137           NA              OS       ECLIA     3.30     91/46      HR    2.21   1.40   2.83
  Edelman      2012     USA       Mixed       NA         PB/NA       IIIB/IV      P       88           NA            PFS/OS     ECLIA     4.18       NA       SC    1.68   1.33   2.11
  Jung         2011    Korea      Asian       NA         TKI/M       IIIB/IV      R      123           NA            PFS/OS     ECLIA     3.30     64/59      HR    2.76   1.38   5.53
  Cedrés       2011    Spain    Caucasion     NA           NA        III--IV      R      183      9.7(1--126)        PFS/OS      IRMA     3.30     119/64     SC    1.52   1.06   2.20
  Hanagiri     2011    Japan      Asian       Yes         PB/A          I         R      341           42              OS        IRMA     2.00    145/196     HR    2.57   1.21   5.44
  Ma           2011    China      Asian       NA           NA           I         R      153       26(2--121)          OS       ECLIA     3.30     41/112     HR    9.81   1.64   58.67
  Jin          2010    China      Asian       No         PB/NA       IIIB/IV      R      111           NA              OS       ELISA     3.50     47/64      HR    1.68   1.05   2.69
  Takahashi    2010    Japan      Asian       NA           NA         I--IV       R      1202          NA              OS       CLEIA    18.00       NA       HR    2.02   1.14   3.58
  Petris       2011   Sweden    Caucasion     NA           NA         I--IV       NA     174           NA              OS       ELISA     6.00       NA       HR    0.80   0.73   1.32
  Tomita       2010    Japan      Asian       Yes          NA         I--III      R      291      60.7--141.7          OS         NA      2.40     58/233     HR    1.57   1.29   1.89
  Nisman       2009   Israel      Asian       No           NA        IIIA--IV     P       88           NA              OS       ELISA     3.20     60/28      RR    1.80   1.10   2.80
  Chen         2010    China      Asian       No         TKI/M       III--IV      R      122           NA              OS       ELISA     3.30     49/73      HR    1.78   1.19   2.65
  Chakra       2008   France    Caucasion     NA           NA         I--IV       P      451           NA              OS        IRMA     3.60    224/227     HR    1.50   1.20   1.86
  Jacot        2008   France    Caucasion     NA           NA         I--IV       P      289    20.8(2.5--34.1)        OS        IRMA     3.60     92/197     HR    2.30   1.52   3.49
  Ishikawa     2008    Japan      Asian       NA         TKI/M       IIIB/IV      R       65     8.3(1.1--37.9)      PFS/OS     ECLIA     2.80     48/17      HR    1.97   0.91   4.27
  Nisman       2008   Israel      Asian       No         PB/Mix      IIIA--IV     P       60           NA              OS       ELISA     3.20     43/37      RR    0.50   0.30   0.90
  Hisashi      2007    Japan      Asian       Yes          NA         I--IV       R      101           73              OS       CLEIA     3.50      6/95      RR    9.79   2.24   42.80
  Matsuoka     2007    Japan      Asian       Yes          NA           I         R      256    35.5(3.7--75.5)        OS       ELISA     2.80     35/221     SC    2.92   2.25   6.84
  Mizuguchi    2007    Japan      Asian       Yes          NA         I--IV       R      272           NA              OS       CLEIA     2.00    149/123     HR    2.42   1.99   2.86
  Barle\'si    2005   France    Caucasion     NA         TKI/NA      IIIB/IV      P       51           NA              OS       ELISA     3.50     13/38      HR    2.45   1.13   5.29
  Muley        2004   Germany   Caucasion     Yes          NA           I         R      153           NA              OS       ELISA     3.30       NA       HR    2.16   1.08   4.29
  Barlesi      2004   France    Caucasion     No          PB/M       IIIB/IV      P      264        9(1--77)           OS       ELISA     3.50    138/126     HR    1.30   1.06   1.78
  Trapé        2003    Spain    Caucasion     No         PB/NA       IIIA--IV     P       48           NA              OS       ECLIA     3.60       NA       HR    1.75   0.93   3.65
  Kulpa        2002   Poland    Caucasion     NA           NA         I--IV       NA     200           NA              OS       ECLIA     3.60     127/73     HR    1.31   0.92   1.87
  Reinmuth     2002   Germany   Caucasion     Yes          NA        I--IIIA      P       66       42(NA-86)           OS       ELISA     3.57     23/43      SC    2.80   0.98   7.99
  Ono          2013    Japan      Asian       No           NA        IIIB/IV      R      284           NA              OS       CLEIA     2.20    134/150     HR    0.43   0.31   0.59
  Ondrej F     2014    Czech    Caucasion     NA         TKI/M       IIIB/IV      R      144           NA            OS/PFS     ELISA     2.50     83/61      HR    2.17   1.48   3.19
  Monik        2014     NA      Gaussian      Yes         None        I--IV       P       50      72.5(4--108)         OS       ELISA     2.10      0.45      SC    1.00   0.45   2.21

HR-E: HR Estimate; R: retrospective; P: prospective; NA: not available; PB/A: Platinum-based/adjuvant chemotherapy; PB/M: Platinum-based/metastatic chemotherapy; PB/mix: Platinum-based/adjuvant chemotherapy and metastatic chemotherapy; TKI/M: TKI/metastatic chemotherapy; TKI/Mix: TKI/adjuvant and metastatic chemotherapy; SC: survival curve; AHR: adjusted hazard ratio; ALL: adjusted lower limit; AUL: adjusted upper limit; ECLIA: electrochemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; CLEIA: chemiluminescent enzyme immunoassay; IRMA: immunoradiometric assay.

###### Main results of the meta-analysis

                           N.of studies   N. of patients     HR(95%CIs)               Heterogeneity test  
  ----------------------- -------------- ---------------- ----------------- -------- -------------------- ---------
  OS                                                                                                           
  Overall                       31             6394        1.60(1.36,1.89)   204.53         85.30%         \<0.001
  Stage                                                                                                        
  I--IIIA                       6              1138        2.18(1.70,2.80)    5.99          16.60%          0.307
  IIIB--IV                      9              1290        1.47(1.02,2.11)   68.04          88.20%         \<0.001
  Mix(I--IV)                    16             3966        1.52(1.24,1.88)   116.06         87.10%         \<0.001
  Surgical intervention                                                                                        
  Surgery                       10             1997        1.94(1.42,2.67)   85.90          89.50%         \<0.001
  Non-surgery                   8              1114        1.24(0.79,1.95)   70.54          90.10%         \<0.001
  Chemotherapy                                                                                                 
  EGFR-TKI                      6              665         1.83(1.31,2.58)   14.84          66.30%          0.011
  Platinum-based                8              1218        1.53(1.18,1.99)   24.67          71.60%          0.001
  Ethnicity                                                                                                    
  Asian                         17             4096        1.62(1.25,2.09)   160.26         90.00%         \<0.001
  Caucasian                     13             2210        1.60(1.31,1.95)   36.48          67.10%         \<0.001
  Sample size                                                                                                  
  Small                         20             2246        1.66(1.35,2.03)   68.62          72.30%         \<0.001
  Large                         11             4148        1.53(1.16,2.00)   130.45         92.30%         \<0.001
  Study design                                                                                                 
  Prospective                   11             1542        1.58(1.27,1.96)   30.18          66.90%          0.001
  Retrospective                 18             4478        1.75(1.38,2.22)   155.27         89.10%         \<0.001
  PFS                                                                                                          
  Overall                       7              1061        1.41(1.19,1.69)   24.54          75.60%         \<0.001

OS: overall survival; HR: hazard ratio; CI: confidence interval; PFS: progression-free survival.
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